{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:40:37Z","timestamp":1784882437763,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"COST action","award":["Euro Cholangio Net"],"award-info":[{"award-number":["Euro Cholangio Net"]}]},{"name":"COST action","award":["Euro Cholangio Net"],"award-info":[{"award-number":["Euro Cholangio Net"]}]},{"name":"CRUK-Scotland Cancer Centre","award":["100006"],"award-info":[{"award-number":["100006"]}]},{"DOI":"10.13039\/501100000589","name":"Chief Scientist Office","doi-asserted-by":"publisher","award":["TCS\/21\/25"],"award-info":[{"award-number":["TCS\/21\/25"]}],"id":[{"id":"10.13039\/501100000589","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>With the increasing of novel therapeutics for the treatment of Biliary Tract Cancers (BTC), and the need to assess their socio-economic impacts for national licence approvals, it is as important as ever to have real-life data in national populations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and results<\/jats:title>\n                <jats:p>We performed an audit of the first 2 year-activity (Sep 2019-Sep 2021) of the centralized West-of-Scotland-BTC clinic. 122 patients accessed the service, including 68% with cholangiocarcinoma (CCA), 27% with gallbladder cancer (GBC), and 5% with ampulla of Vater carcinoma with biliary phenotype (AVC). Median age at diagnosis was 66 (28\u201384), with 30% of newly diagnosed patients being younger than 60 years-old. Thirty-five cases (29%) underwent surgery, followed by adjuvant-chemotherapy in 66%. 60% had recurrent disease (80% with distant relapse). Sixty-four patients (58%) started first-line Systemic-AntiCancer-Treatment (SACT). Of these, 37% received second line SACT, the majority of which had iCCA and GBC. Thirty-% of those who progressed received third line SACT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>About 30% of BTC were eligible for curative surgery. Fifty-eight and twenty% of the overall cohort of advanced BTC patients received first and second line SACT. Our data suggest that reflex genomic profiling may not be cost-effective until molecularly driven strategies are limited to second line setting.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12279-6","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T10:02:15Z","timestamp":1715853735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Insights for clinical management from the real-life data of the centralized West of Scotland biliary cancer clinic"],"prefix":"10.1186","volume":"24","author":[{"given":"Valentina","family":"Zanuso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamsin","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Casolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ona","family":"Pallise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Braconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"issue":"9","key":"12279_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"12279_CR2","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s41416-020-0987-3","volume":"123","author":"JJG Marin","year":"2020","unstructured":"Marin JJG, Prete MG, Lamarca A, Tavolari S, Landa-Magdalena A, Brandi G, et al. Current and novel therapeutic opportunities for systemic therapy in biliary cancer. Br J Cancer. 2020;123(7):1047\u201359.","journal-title":"Br J Cancer"},{"issue":"2","key":"12279_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340.","journal-title":"Ann Oncol"},{"issue":"5","key":"12279_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663\u201373.","journal-title":"Lancet Oncol"},{"issue":"24","key":"12279_CR5","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.3748\/wjg.v29.i24.3825","volume":"29","author":"A Zalin-Miller","year":"2023","unstructured":"Zalin-Miller A, Jose S, Knott C, Paley L, Tataru D, Morement H, et al. Regional variation in routes to diagnosis of cholangiocarcinoma in England from 2006 to 2017. World J Gastroenterol. 2023;29(24):3825\u201342.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"12279_CR6","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796\u2013807.","journal-title":"Lancet Oncol"},{"key":"12279_CR7","doi-asserted-by":"crossref","unstructured":"Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 20211;7(11):1669\u20131677.","DOI":"10.1001\/jamaoncol.2021.3836"},{"issue":"5","key":"12279_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671\u201384.","journal-title":"Lancet Oncol"},{"issue":"3","key":"12279_CR9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","volume":"36","author":"M Javle","year":"2018","unstructured":"Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, et al. Phase II study of BGJ398 in patients with FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018;36(3):276\u201382.","journal-title":"J Clin Oncol"},{"issue":"2","key":"12279_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","volume":"12","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT, et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with Advanced Solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study. Cancer Discov. 2022;12(2):402\u201315.","journal-title":"Cancer Discov"},{"issue":"suppl16","key":"12279_CR11","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1200\/JCO.2022.40.16_suppl.4009","volume":"40","author":"L Goyal","year":"2022","unstructured":"Goyal L, Meric Bernstam F, Hollebecque A, Morizane C, Valle JW, Karasic TB, et al. Updated results of the FOENIX-CCA2 trial: efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions\/rearrangements. J Clin Oncol. 2022;40(suppl16):4009.","journal-title":"J Clin Oncol"},{"issue":"9","key":"12279_CR12","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","volume":"21","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Lassen U, \u00c9lez E, Italiano A, Curigliano G, Javle M, et al. Dabrafenib plus Trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234\u201343.","journal-title":"Lancet Oncol"},{"issue":"9","key":"12279_CR13","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","volume":"22","author":"M Javle","year":"2021","unstructured":"Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021;22(9):1290\u2013300.","journal-title":"Lancet Oncol"},{"issue":"6","key":"12279_CR14","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","volume":"36","author":"JD Hainsworth","year":"2018","unstructured":"Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, et al. Targeted therapy for Advanced Solid tumors on the basis of Molecular profiles: results from MyPathway, an Open-Label, phase IIa multiple Basket Study. J Clin Oncol. 2018;36(6):536\u201342.","journal-title":"J Clin Oncol"},{"issue":"suppl16","key":"12279_CR15","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2022.40.16_suppl.4079","volume":"40","author":"JJ Harding","year":"2022","unstructured":"Harding JJ, Piha-Paul SA, Shah RH, Cleary JM, Quinn DI, Brana I, et al. Targeting HER2 mutationpositive advanced biliary tract cancers with neratinib: final results from the phase 2 SUMMIT basket trial. J Clin Oncol. 2022;40(suppl16):4079.","journal-title":"J Clin Oncol"},{"issue":"suppl3","key":"12279_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1200\/JCO.2021.39.3_suppl.299","volume":"39","author":"F Meric-Bernstam","year":"2021","unstructured":"Meric-Bernstam F, Hanna DL, El-Khoueiry AB, Kang Y-K, Oh D-Y, Chaves JM, et al. Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): results from a phase I study. J Clin Oncol. 2021;39(suppl3):299.","journal-title":"J Clin Oncol"},{"issue":"suppl16","key":"12279_CR17","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","volume":"40","author":"A Ohba","year":"2022","unstructured":"Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial). J Clin Oncol. 2022;40(suppl16):4006.","journal-title":"J Clin Oncol"},{"issue":"5","key":"12279_CR18","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","volume":"76","author":"L Izquierdo-Sanchez","year":"2022","unstructured":"Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Kl\u00fcmpen HJ, et al. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022;76(5):1109\u201321.","journal-title":"J Hepatol"},{"issue":"14","key":"12279_CR19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. ABC-02 Trial investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"key":"12279_CR20","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, Chen L-T, Okusaka T, Vogel A, Oh DY, Ruth He A, Qin S, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced biliary tract Cancer. NEJM Evid. 2022;1:EVIDoa2200015.","journal-title":"NEJM Evid"},{"issue":"10","key":"12279_CR21","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.3390\/cancers14102389","volume":"14","author":"LE Nooijen","year":"2022","unstructured":"Nooijen LE, Banales JM, de Boer MT, Braconi C, Folseraas T, Forner A, et al. Impact of positive lymph nodes and resection margin status on the overall survival of patients with Resected Perihilar Cholangiocarcinoma: the ENSCCA Registry. Cancers (Basel). 2022;14(10):2389.","journal-title":"Cancers (Basel)"},{"issue":"16","key":"12279_CR22","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","volume":"30","author":"AM Horgan","year":"2012","unstructured":"Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934\u201340.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12279-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12279-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12279-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T10:02:52Z","timestamp":1715853772000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12279-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12279"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12279-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Competing Interests: CB received honoraria as speaker (Astrazeneca, Incyte, Servier) and consultant (Incyte, Servier, Boehringer Ingelheim, Astrazeneca), received research funds (Avacta, Medannex, Servier) and her spouse is an employee of Astrazeneca. VZ, TN, RC, GA, OP and JM have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the ethical Caldicott committee for NHS Greater Glasgow & Clyde on 7\/12\/2021 (Demographics and Clinical Characteristics of Patients with Biliary Tract Cancer in Scotland), and was given the approval for clinical audit and publication. No identifiable information are present in this manuscript as per application. Informed consent was not obtained as per Sect.\u00a060 of the Health and Social Care Act 2001, given this is a retrospective study and does not contain identifiable information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"597"}}